Key Highlights: Implications: Zytorvi’s approval strengthens Dr. Reddy’s position in India’s esophageal cancer market by expanding access to first-line PD-1 immunotherapy without PD-...
Key Highlights: Implications: Dr. Reddy’s launch of Nivorz marks its entry into India’s biosimilar immuno‑oncology segment and adds a lower‑cost checkpoint inhibitor option across 12 appro...
Key Highlights: Implications: Relopduo gives BMS a next‑generation immunotherapy in India’s melanoma market, combining PD‑1 and LAG‑3 blockade to offer materially better pro...
